Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
Publication Date: August 8, 2016
Key Points
Key Points
Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Assessment
Assessm...
...uspected stage IIIC or IV invasive epith...
...ary clinical evaluation should include...
Treatment
...eatment...
...k Factors for Perioperative Morbidity or Mortality...
...o have a high perioperative risk pro...
...that women are not eligible for me...
...women who are fit for PCS, with po...
...high likelihood of achieving cytoreduction to...
...o are fit for PCS but are deemed unlikely to have...
...e NACT is delivered, all patients should have...
...a platinum/taxane doublet is recommended. ( EB...
...urgery following three or four cycles of che...
...ts with progressive disease on NACT have a poor...
Clinical Evaluation and Treatment of W...